paclitaxel has been researched along with Allergy, Drug in 213 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (1.88) | 18.7374 |
| 1990's | 68 (31.92) | 18.2507 |
| 2000's | 72 (33.80) | 29.6817 |
| 2010's | 43 (20.19) | 24.3611 |
| 2020's | 26 (12.21) | 2.80 |
| Authors | Studies |
|---|---|
| Culmone, K; Mendez, S; Ramos, R; Sweeney-Moore, A | 1 |
| Hwang, WY; Kim, JH; Kim, K; Kim, YB; Lee, M; No, JH; Suh, DH | 1 |
| Casas-Murillo, CA; González-Díaz, SN; López-Méndez, A; Santos-Fernández, WJ; Solís-Lara, H; Vidal-Gutiérrez, O; Villarreal-González, RV; Zayas-Villanueva, OA | 1 |
| ALMuhizi, F; Copaescu, AM; De Las Vecillas Sanchez, L; Gilbert, L; Isabwe, GAC | 1 |
| Chambers, P; Foreman, E; Polwart, C; Walker, A | 1 |
| Amorntrakoon, P; Chantharakhit, C; Mungkornkaew, S; Ruchakorn, T; Sujaritvanichpong, N; Tassanamethee, S; Theeratrakul, P | 1 |
| Castellano Copa, P; Iglesias-Santamaría, A | 1 |
| Haine, AI; Notenboom, CMAW; Ruiter, R; Tan, LVP; van der Deure, WM | 1 |
| Biagioni, B; Cortellini, G; Liberati, S; Lippolis, D; Piscaglia, F; Raiteri, A | 1 |
| Costa, J; Jabaley, T; Lynch, DM; Mazzola, E; Menon, S | 1 |
| Abelé, M; Aelbrecht-Meurisse, C; Carnot, A; Feutry, F; Gaboriau, L; Le Deley, MC; Léguillette, C; Marliot, G; Sakji, I; Strobbe, G; Villain, A | 1 |
| Bulut, İ; Yegin Katran, Z | 1 |
| Han, JY; Li, CY; Li, GQ; Li, XL; Liang, AH; Liu, SY; Pan, C; Tian, JZ; Wang, LM; Xian, Z; Yi, Y; Zhang, YS; Zhao, Y | 1 |
| Chung, SJ; Kang, DY; Kang, HR; Kim, YC; Lee, JH; Lee, KH; Lee, SY; Moon, M; Oh, J; Yun, J | 1 |
| Brás, R; Caiado, J; Castells, M; Costa, L; Paulino, M | 1 |
| Gomes, ML; Katib, N; Narroway, HG; Thomas, SD; Varcoe, RL | 1 |
| Jošt, M; Kopač, P; Koren, A; Korošec, P; Lainščak, M; Mangaroski, D | 1 |
| Pimsi, P; Saengsukkasemsak, N; Santimaleeworagun, W; Thangwonglers, T; Therasakvichya, S | 1 |
| Arcangeli, M; Baldari, B; D'Errico, S; Fineschi, V; Frati, P; Santurro, A | 1 |
| Berger, M; Folan, S; Li, J; Nymberg, K; VanDeusen, J; Vargo, C; Zanath, K | 1 |
| Bhutta, OA; Khan, I; Masood, W; Saleem, Z; Shammas, S | 1 |
| Aoyama, Y; Harada, H; Hoshino, K; Kagami, S; Kinjo, Y; Kuradome, Y; Murakami, M; Ueda, T; Yoshino, K | 1 |
| Gelderblom, H; Zwaveling, J | 1 |
| Boere, IA; Bosch, TM; Cox, JM; Jager, A; Malmberg, R; Mathijssen, RHJ; Oomen-de Hoop, E; van den Bemt, PMLA; van Doorn, L; van Leeuwen, RWF | 1 |
| Cruz, RAC; Díaz, SNG; González, RVV; Gutiérrez, OV; Quezada, CEL | 1 |
| Alfaya Arias, T; Alonso-Díaz-de-Durana, MD; Álvarez-Twose, I; González-Bravo, L; Laiseca García, J; Nieto Nieto, A; Tejedor Alonso, MA | 1 |
| Biedermann, S; Colevas, AD; He, Z; Lansinger, OM | 1 |
| Aizawa, Y; Aoyama, T; Furuya, K; Goto, T; Ishibashi, H; Iwahashi, H; Kato, K; Miyamoto, M; Moriiwa, M; Nagaoka, I; Nakatsuka, M; Sasa, H; Shimizu, Y; Soyama, H; Suguchi, Y; Takano, M; Tsuda, H; Yajima, I; Yoshikawa, T | 1 |
| Mahdi, H; Maurer, K; Michener, C; Rose, PG | 1 |
| Jeerakornpassawat, D; Suprasert, P | 1 |
| Picard, M | 1 |
| Boggiani, D; Musolino, A; Palli, D; Pellegrino, B; Tommasi, C | 1 |
| Laoitthi, P; Parinyanitikul, N; Poovorawan, N; Rattananupong, T; Sithidetphaiboon, P; Sriuranpong, V; Tanpipattanakul, W; Thanasanvimon, S | 1 |
| Chowdhury, MR; Goto, M; Kamiya, N; Moniruzzaman, M; Moshikur, RM; Tahara, Y; Wakabayashi, R | 2 |
| Castro, SN; de Castro Baccarin, AL; de Iracema Gomes Cubero, D; Del Giglio, A; Irene, MN; Luz, AS; Móz, LES; Sordi, R | 1 |
| Wu, HL | 1 |
| Bavbek, S; Bonadonna, P; Caralli, M; Castells, M; Cernadas, J; Cortellini, G; Costantino, MT; Dursun, AB; Gelincik, A; Lucchini, G; Pagani, M | 1 |
| Durham, CG; Foster, J; Herrington, JD; Sager, L; Thotakura, D | 1 |
| Li, L; Sun, T | 1 |
| Armstrong, DK; Coleman, RL; Phillips, M; Weil, SC; White, AJ | 1 |
| Agarwal, R; Blagden, S; Carty, K; Gabra, H; Kwon, JS; Mahmoud, S; O'Cathail, SM; O'Sullivan, P; Shaboodien, R; Whear, S | 1 |
| Jílek, P; Rezáč, A; Rezáčová, V; Sedláková, I; Skapinec, P; Spaček, J; Tošner, J | 1 |
| Aono, K; Asano, M; Kato, T; Ouchi, A; Watanabe, T | 1 |
| Berger, MJ; Layman, R; Lustberg, MB; Macrae, E; Mrozek, E; Phillips, G; Ramaswamy, B; Shapiro, CL; Shaver, K; Vargo, C; Vincent, M; Wesolowski, R | 1 |
| Ageshio, F; Kagawa, H; Kimura, H; Matsui, H; Mori, M; Niinaka, M; Satomi, A; Uenami, T; Yamaguchi, T; Yano, Y; Yokota, S; Yoneda, T | 1 |
| Katsumata, N; Sugano, T | 1 |
| Aramendía, JM; D'Amelio, CM; Fusco, JP; Gastaminza, G; Goikoetxea, MJ; Yuste, JR | 1 |
| Hasuo, Y; Ichinoe, A; Kato, K; Kobayashi, H; Masuda, S; Nishida, M; Ogawa, S; Ohgami, T; Saito, T; Sakai, K; Shimokawa, M; Sonoda, K; Ueoka, Y; Yahata, H | 1 |
| Berlin, ST; Caiado, J; Campos, SM; Castells, MC; Galvão, VR; Giavina-Bianchi, P; Matulonis, UA; Picard, M; Pur, L | 1 |
| Chaithongwongwatthana, S; Yanaranop, M | 1 |
| Hood, AP; Merl, MY; Nguyen, LH; Yenilmez, A | 1 |
| Chen, FC; Li, LJ; Wang, LH; Zhang, J; Zhang, XM; Zheng, XY | 1 |
| Farquharson, F; Lake, E; Twigg, M | 1 |
| Arenare, L; Bergamini, A; Cecere, SC; Della Pepa, C; Di Napoli, M; Facchini, G; Gargiulo, P; Mangili, G; Pignata, S; Pisano, C; Rossetti, S; Tambaro, R | 1 |
| Akase, T; Doi, M; Harada, T; Yamada, Y | 1 |
| Mahler, V; Pfoch, L; Sticherling, M | 1 |
| Dana, W; Gerber, DL; Lal, LS; Lau, J | 1 |
| Batsolaki, M; Chiladakis, JA; Gouvelou-Deligianni, GV; Kounis, GN; Kounis, NG; Kounis, SA; Soufras, GD | 1 |
| Billinger, M; Flueckiger, A; Hess, OM; Meier, P; Mettler, D; Schaffner, T; Strahm, Y; Studer, U | 1 |
| Bahleda, R; Cadranel, J; Ferte, C; Gomez-Roca, C; Loriot, Y; Moldovan, C; Soria, JC; Wislez, M | 1 |
| Fader, AN; Rose, PG | 1 |
| Gothwal, R; Kumar, A | 1 |
| Eguchi, H; Kogure, Y; Komatsubara, K; Matsuhisa, T; Miyoshi, K | 1 |
| Pineda de la Losa, F; Prieto García, A | 1 |
| Pagani, M | 1 |
| Baricordi, OR; Ferlini, A; Indelli, M; Lelli, G; Rimessi, P; Rizzo, R; Spaggiari, F | 1 |
| Eto, S; Goromaru, T; Hase, Y; Morita, N; Ochi, Y; Shinohara, Y; Takahashi, K | 1 |
| Farooq, V; Gogas, BD; Serruys, PW | 1 |
| Boman, K; Dell'Anna, T; Donoghoe, M; Fabbro, M; Ferrandina, G; Huober, J; Joly, F; Pujade-Lauraine, E; Ray-Coquard, I; Reinthaller, A; Sugimoto, A; Vaughan, M; Vergote, I | 1 |
| Brown, JB; Kadoyama, K; Kuwahara, A; Okuno, Y; Sakaeda, T; Yamamori, M | 1 |
| Berger, MJ; Dunlea, LJ; Lustberg, MB; Phillips, GS; Rettig, AE; Shapiro, CL | 1 |
| Alba, E; García-Tapiador, A; González-Sánchez, LA; Jiménez, B; Medina, L; Navarro, V; Romero-García, G; Sánchez-Muñoz, A | 1 |
| Benemei, S; Creminon, C; Fusi, C; Geppetti, P; Materazzi, S; Nassini, R; Nilius, B; Patacchini, R; Pedretti, P; Prenen, J | 1 |
| Baima Poma, C; Ferrero, A; Martra, F; Modaffari, P; Perotto, S; Piovano, E; Pivetta, E; Tripodi, E; Zanfagnin, V; Zola, P | 1 |
| Harvey, JE; Kapadia, SR; Kataoka, Y; Martin, J; Nicholls, SJ; Puri, R; Tuzcu, EM | 1 |
| Dea, G; Gandara, D; Lara, P; Lau, D; Quock, J; Tanaka, M | 1 |
| Ficorella, C; Marchetti, P; Narducci, F; Paris, I; Porzio, G; Ricevuto, E | 1 |
| Bagaméri, A; Lehoczky, O; Pulay, T | 1 |
| Andersson, H; Boman, K; Parö, G; Puistola, U; Ridderheim, M; Rosenberg, P; Sorbe, B | 1 |
| He, L; Wang, GL; Zhang, Q | 2 |
| Bagaméri, A; Lehoczky, O; Pulay, T; Udvary, J | 1 |
| Ando, M; Katsumata, N; Mukai, H; Watanabe, T | 1 |
| Markman, M | 1 |
| Ellis, GK; Garrison, JA; Gralow, JR; Linden, HM; Livingston, RB; McCune, JS; West, HL | 1 |
| Emerich, J; Kobierski, J; Majdak, E; Mielcarek, P | 1 |
| Sakashita, A; Sato, A; Taguchi, S | 1 |
| Goromaru, T; Hirakawa, T; Itoh, Y; Nakano, H; Oishi, R; Sendo, T; Takasaki, S; Yahata, H | 1 |
| Gruenigen, VE; McElroy, TM; Waggoner, SE | 1 |
| den Bakker, MA; Gelderblom, H; Kloover, JS; van Meerbeeck, JP | 1 |
| Goromaru, T; Hirakawa, T; Itoh, Y; Nakano, H; Oishi, R; Sendo, T; Takasaki, S | 1 |
| Bamba, M; Kobayashi, TK; Moritani, S; Muramatsu, M; Nishino, T; Ueda, M; Urabe, M | 1 |
| Ardavanis, A; Baziotis, N; Gerasimidis, G; Rigatos, G; Tryfonopoulos, D; Yiotis, I | 1 |
| Goromaru, T; Hirakawa, T; Itoh, Y; Nakano, H; Oishi, R; Sakai, N; Sendo, T | 1 |
| Choi, J; Fulcher, DA; Harnett, P | 1 |
| Goromaru, T; Ikesue, H; Itoh, Y; Kobayashi, K; Oishi, R; Sendo, T; Yano, T | 1 |
| Castells, M; Feldweg, AM; Lee, CW; Matulonis, UA | 1 |
| Adamson, B; Braverman, AS; McManus, M; Pierre, S; Rao, S; Salvatti, ME | 1 |
| Castells, MC; Lee, CW; Matulonis, UA | 1 |
| Bhar, P; Desai, N; Doval, D; Hortobagyi, GN; Ibrahim, NK; Nair, MK; Page, R; Patel, KM; Rao, SC; Samuels, B | 1 |
| Disilvestro, P; Dizon, DS; Gordinier, ME; Granai, CO; Legare, RD; Miller, J; Moore, R; Pires, L; Rojan, A; Schwartz, J | 1 |
| Birk, CL; Brown, JV; Goldstein, BH; Micha, JP; Rettenmaier, MA | 1 |
| Ballard, EE; Dowell, JE; Hunt, WC; Jumper, CA; Krieger, JA; Rabinowitz, I; Shah, SR; Stanford, BL | 1 |
| Hirakawa, T; Itoh, Y; Nakano, H; Oishi, R; Saito, M; Sendo, T; Uchida, M; Yahata, H | 1 |
| Alvarez, J; Belknap, SM; Bennett, CL; Davidson, CJ; Davidson, L; Feldman, MD; Gage, JE; Gligoric, G; Hoffman, JM; McKoy, JM; Morse, RE; Nebeker, JR; Raisch, DW; Samore, MH; Virmani, R; West, DP; Whisenant, BK; Yarnold, PR | 1 |
| Azarbal, B; Currier, JW | 1 |
| Kamiyama, K; Morikawa, T; Nakata, J; Sakata, N; Sato, S; Seki, K; Tominaga, T; Wada, N; Wada, Y; Yamatoya, Y | 1 |
| Burstein, HJ; Come, SE; Gelman, R; Haldoupis, M; Lin, NU; Parker, LM; Ryabin, N; Shulman, LN; Winer, EP | 1 |
| Bander, R; Bukacel, DG; Ibrahim, RB | 1 |
| Harish, CR; Satish, B; Tressa, K | 1 |
| Furukawa, M; Hirashima, T; Kawase, I; Kobayashi, M; Matsui, K; Nakamura, Y; Nitta, T; Sasada, S; Takimoto, T | 1 |
| Hahalis, G; Kounis, NG; Theoharides, TC | 1 |
| Akerman, P; Dipetrillo, T; Doyle, LA; Evans, D; Kennedy, N; Kennedy, T; Krasna, M; Ng, T; Plette, A; Safran, H; Spector, J; Suntharalingam, M; Wanebo, H | 1 |
| Dufresne, A; Pivot, X; Viel, E; Villanueva, C | 1 |
| Abzah, A; Farraj, Z; Friedman, E; Hussein, O; Tamam, S; Zidan, J | 1 |
| Goto, T; Maezawa, K; Matsubara, T; Mizukami, H; Nemoto, H; Saito, M; Sanada, Y; Sasaya, S; Yoshizawa, Y | 1 |
| Fumoleau, P; Lemevel, B; Maugard-Louboutin, C; Perrocheau, G | 1 |
| Alberti, D; Arzoomanian, R; Feierabend, C; Schiller, JH; Spriggs, D; Storer, B; Tutsch, K | 2 |
| Aamdal, S; Franklin, HR; Kaplan, S; Kerger, J; Paridaens, R; Schachter, J; Verweij, J; Wanders, J; Wolff, I | 1 |
| DeLisa, AF; Gregory, RE | 1 |
| Goldberg, HL; Vannice, SB | 1 |
| Benner, S; Calayag, M; Fossella, FV; Glisson, B; Huber, M; Lee, JS; Lippman, S; Murphy, WK; Perez-Soler, R; Shin, DM | 1 |
| Donehower, RC; Rowinsky, EK | 1 |
| Angel, C; Del Priore, G; Dubeshter, B; Smith, P; Warshal, DP | 1 |
| Laskin, MS; Lucchesi, KJ; Morgan, M | 1 |
| Friedland, D; Gorman, G; Treat, J | 1 |
| Walker, FE | 1 |
| Lilley, LL; Scott, HB | 1 |
| Calzone, K; McCauley, DL; Wicha, M | 1 |
| Foa, R; Norton, L; Seidman, AD | 1 |
| Eisenhauer, EA; Ernst, S; Jolivet, J; Mertens, WC; Moore, M; Muldal, A | 1 |
| Burroughs, J; Canetta, R; Catane, R; Dougan, M; Grechko, J; Onetto, N; Rozencweig, M; Winograd, B | 1 |
| Greco, FA; Hainsworth, JD | 1 |
| Dorr, RT | 1 |
| Finley, RS; Rowinsky, EK | 1 |
| Burris, HA | 1 |
| Abbruzzese, JL; Ajani, JA; Bready, B; Lassere, Y; Levin, B; Patt, Y; Pazdur, R; Soh, LT; Soo, E; Sugarman, S | 1 |
| Jeffers, S; Muggia, F; Uziely, B | 1 |
| Gelmon, K | 1 |
| Akerley, W; Choy, H; Clark, J; Glantz, M; Leone, L; Papa, A; Puthawala, Y; Rege, V; Safran, H; Soderberg, C | 1 |
| Donehower, RC; Eisenhauer, EA; Gianni, L; Hubbard, JL; McGuire, WP; Onetto, N; Peereboom, DM; Piccart, M; Rowinsky, EK | 1 |
| Arbuck, SG; Chaudhry, V; Donehower, RC; Eisenhauer, EA; Rowinsky, EK | 1 |
| Lubejko, BG; Sartorius, SE | 1 |
| Arbuck, SG; Canetta, R; Christian, MC; Onetto, N | 1 |
| Dirix, L; Kaye, S; Prove, A; Schrijvers, D; van Oosterom, A; Vonck, I; Wanders, J | 1 |
| Belani, CP; Ramanathan, RK | 1 |
| Bell, DR; Bishop, JF; Friedlander, M; Goldstein, D; Levi, JA; Millward, MJ; Olver, IN; Rischin, D; Smith, JG; Toner, GC | 1 |
| Balmaceda, C; Baselga, J; Bruno, R; Crown, JP; Currie, V; Freilich, R; Gilewski, TA; Gollub, M; Hakes, TB; Hudis, CA; Lebwohl, DE; Norton, L; Raptis, G; Robles, M; Seidman, AD | 1 |
| Barnes, CS; Cowan, KH; Denicoff, AM; Goldspiel, BR; Gossard, MR; Kohler, DR; McCabe, M; Noone, MH; O'Shaughnessy, JA; Tolcher, AW; Zujewski, J | 1 |
| Colarusso, PJ; Essayan, DM; Kagey-Sobotka, A; King, ED; Lichtenstein, LM; Ozols, RF | 1 |
| Punt, CJ; van Herpen, CM; van Hoesel, QG | 1 |
| Boehm, DK; Maksymiuk, AW | 1 |
| Essayan, DM; Kagey-Sobotka, A; Lichtenstein, LM | 1 |
| Nishiwaki, Y; Saijo, N; Sasaki, Y; Tamura, T | 1 |
| Choy, H; Cole, BF; Yee, L | 1 |
| Ariyoshi, Y; Fukuoka, M; Furuse, K; Hara, N; Ikegami, H; Kimura, I; Kurita, Y; Niitani, H; Nishiwaki, Y; Saijo, N; Yoneda, S | 1 |
| Belani, CP; Holbert, JM; Ramanathan, RK; Reddy, VV | 1 |
| Conte, PF; Gennari, A; Salvadori, B; Tognoni, A | 1 |
| Diergarten, K; Goes-Schmieder, R; Kober, B; Kolotas, C; Martin, T; Mitrou, PS; Schneider, LV; Vogt, HG; Zamboglou, N | 1 |
| Rodenhuis, S; ten Bokkel Huinink, WW; Westermann, AM | 1 |
| Bajorin, DF; Hilton, S; Kelly, WK; Mazumdar, M; McCaffrey, JA; Sadan, S; Scher, HI | 1 |
| Ciesielski-Carlucci, C; Jacobs, C; Leong, P | 1 |
| Bookman, MA; Kloth, DD; Kover, PE; Ozols, RF; Smolinski, S | 2 |
| Kaern, J; Kristensen, G; Rosenberg, P; Sorbe, B; Tropé, C | 1 |
| Belinson, J; Kennedy, A; Kulp, B; Markman, M; Peterson, G; Webster, K | 5 |
| Anderson, B; Buller, RE; Olson, JK; Sood, AK; Sorosky, JI | 1 |
| Alving, CR; Muggia, FM; Szebeni, J | 1 |
| Saijo, N; Sekine, I; Yamazaki, S | 1 |
| Birk, C; Brown, JV; Dillman, R; Fraser, P; Micha, JP; Rettenmaier, MA | 1 |
| Etienne, B; Guérin, JC; Nesme, P; Pérol, M; Robinet, G; Vuillermoz, S | 1 |
| Thomas, M | 1 |
| Anderson, N; Lokich, J | 1 |
| Androulakis, N; Bahlitzanakis, N; Georgoulias, V; Giatromanolaki, A; Kakolyris, S; Kamilaki, M; Kotsakis, A; Koukouraki, S; Koukourakis, MI; Kourousis, C | 1 |
| Miyata, Y; Nakanomyo, H; Nishiwaki, Y; Ohtsu, T; Saijo, N; Sasaki, Y; Tamura, T | 1 |
| Canfield, VA; Geyer, CE; Goodwin, DK; Green, SJ; Martino, S; Meyers, FJ; Moinpour, CM; O'Sullivan, J; Osborne, CK | 1 |
| Labovich, TM | 1 |
| Carriero, C; Cazzolla, A; Cormio, G; Cramarossa, D; Di Gesù, G; Di Vagno, G; Loverro, G; Melilli, GA; Selvaggi, L | 1 |
| Grosen, E; Larrison, E; Roecker, E; Siitari, E; Tiggelaar, C | 1 |
| Kearney, K; Myers, JS | 1 |
| Briasoulis, E; Karavasilis, V; Pavlidis, N | 1 |
| Ito, Y | 1 |
| Bevers, M; Freedman, R; Kavanagh, JJ; Kudelka, AP; Moon, C; Verschraegen, CF | 1 |
| Bernstein, BJ | 1 |
| Arditti, J; Catalin, J; Chastagner, P; Doz, F; Frappaz, D; Gentet, JC; Iliadis, A; Moretti, S; Pein, F; Tellingen, OV; Vassal, G | 1 |
| Borgmeier, A; Flentje, M; Huber, RM; Kirschner, J; Lang, S; Schmidt, M; Willner, J | 1 |
| Alving, CR; Barenholz, Y; Danino, D; Priev, A; Savay, S; Szebeni, J; Talmon, Y | 1 |
| Sparreboom, A; van Zuylen, L; Verweij, J | 1 |
| Heymanns, J; Köppler, H; Weide, R | 1 |
| Bodurka-Bevers, DC; Gershenson, DM; Robinson, JB; Singh, D; Wharton, JT; Wolf, JK | 1 |
| Arnaouti, T; Giannikos, L; Giannopoulos, A; Kalahanis, N; Karatzas, G; Kosmas, C; Polyzos, A; Sfikakis, PP; Tsavaris, N; Tsigris, C | 1 |
| Kintzel, PE | 1 |
| Boku, N; Hyodo, I; Miyata, Y; Ohtsu, A; Saitoh, H; Shirao, K; Taguchi, T; Yamada, Y | 1 |
| Markman, M; Zanotti, KM | 1 |
| Elit, L; Finn, M; Hirte, H; Kwon, JS; Mazurka, J; Moens, F; Trim, K | 1 |
| Bonazzi, C; Buda, A; Cantù, MG; Colombo, N; Dell'Anna, T; Floriani, I; Parma, G; Rossi, R; Torri, V | 1 |
| Abdi, EA; Denman, JP; Gilbar, PJ | 1 |
| Weiss, RB | 1 |
| Baker, JR; Donehower, RC; Gralla, RJ; Leyland-Jones, B; Ohnuma, T; Trump, DL; Van Echo, DA; Von Hoff, DD; Weiss, RB; Wiernik, PH | 1 |
| Gralla, RJ; Kris, MG; O'Connell, JP; Parente, RM; Schiff, PB; Wertheim, MS; Young, CW | 1 |
| Dutcher, JP; Einzig, A; Lipton, RB; Schwartz, EL; Strauman, JJ; Wiernik, PH | 1 |
| Donehower, RC; Ettinger, DS; Grochow, LB; Longnecker, SM; Rowinsky, EK | 1 |
| Alberti, DB; Grem, JL; Simon, KJ; Swaminathan, S; Tormey, DC; Trump, DL; Tutsch, KD; Willson, JK | 1 |
| de Vos, FY; van Laarhoven, HM | 1 |
36 review(s) available for paclitaxel and Allergy, Drug
| Article | Year |
|---|---|
Premedication Protocols to Prevent Hypersensitivity Reactions to Chemotherapy: a Literature Review.
Topics: Drug Hypersensitivity; Histamine Antagonists; Humans; Paclitaxel; Premedication; Taxoids | 2022 |
Hypersensitivity Reaction to Carboplatin in Gynecologic Cancer: A Case Report and a Review of the Literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Cisplatin; Drug Hypersensitivity; Drug Substitution; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome; Uterine Neoplasms | 2021 |
Management of Hypersensitivity Reactions to Taxanes.
Topics: Allergens; Animals; Antineoplastic Agents; Bridged-Ring Compounds; Desensitization, Immunologic; Docetaxel; Drug Hypersensitivity; Humans; Paclitaxel; Skin Tests; Taxoids | 2017 |
Nab-paclitaxel after docetaxel hypersensitivity reaction: case report and literature review.
Topics: Aged; Albumins; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Cross Reactions; Docetaxel; Drug Hypersensitivity; Female; Humans; Paclitaxel; Taxoids | 2017 |
Meta-analysis of the effects of oral and intravenous dexamethasone premedication in the prevention of paclitaxel-induced allergic reactions.
Topics: Administration, Oral; Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; China; Dexamethasone; Drug Hypersensitivity; Humans; Injections, Intravenous; Neoplasms; Paclitaxel; Premedication | 2017 |
The complex clinical picture of presumably allergic side effects to cytostatic drugs: symptoms, pathomechanism, reexposure, and desensitization.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Asparaginase; Carboplatin; Cisplatin; Cytostatic Agents; Desensitization, Immunologic; Docetaxel; Drug Hypersensitivity; Humans; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Procarbazine; Risk Factors; Taxoids; Teniposide | 2010 |
Restenosis: delineating the numerous causes of drug-eluting stent restenosis.
Topics: Angioplasty, Balloon, Coronary; Atherosclerosis; Coronary Restenosis; Drug Hypersensitivity; Drug-Eluting Stents; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Paclitaxel; Shear Strength; Sirolimus | 2011 |
Managing taxane toxicities.
Topics: Antineoplastic Agents, Phytogenic; Arthralgia; Bridged-Ring Compounds; Docetaxel; Drug Hypersensitivity; Humans; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Taxoids; Thrombocytopenia | 2003 |
Myalgias and arthralgias associated with paclitaxel.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Phytogenic; Arthralgia; Dose-Response Relationship, Drug; Drug Hypersensitivity; Humans; Incidence; Paclitaxel; Pleurodynia, Epidemic; Severity of Illness Index | 2003 |
[Hypersensitivity reactions to cancer chemotherapeutic agents].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Cisplatin; Drug Eruptions; Drug Hypersensitivity; Fever; Histamine H1 Antagonists; Humans; Lymphoma, Non-Hodgkin; Neoplasms; Paclitaxel; Respiration Disorders; Rituximab; Trastuzumab | 2003 |
Coronary stents, hypersensitivity reactions, and the Kounis syndrome.
Topics: Coronary Artery Disease; Coronary Restenosis; Coronary Thrombosis; Drug Hypersensitivity; Drug-Eluting Stents; Humans; Paclitaxel; Risk Factors; Vasoconstriction | 2007 |
[Efficacy and safety of ixabepilone (BMS-247550), a novel epothilone B analogue].
Topics: Animals; Bone Marrow; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Hypersensitivity; Drug Resistance, Neoplasm; Epothilones; Female; Humans; Male; Maximum Tolerated Dose; Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Taxoids; Tubulin Modulators | 2008 |
[Paclitaxel (Taxol) and docetaxel (Taxotere): results of phase II trials in monochemotherapy].
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials, Phase II as Topic; Docetaxel; Drug Administration Schedule; Drug Hypersensitivity; Drug Tolerance; Female; Humans; Male; Neoplasms; Neutropenia; Organoplatinum Compounds; Paclitaxel; Taxoids | 1995 |
Paclitaxel: a new antineoplastic agent for refractory ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Hypersensitivity; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Melanoma; Ovarian Neoplasms; Paclitaxel; Recombinant Proteins | 1993 |
Paclitaxel (taxol)
Topics: Arrhythmias, Cardiac; Breast Neoplasms; Drug Hypersensitivity; Female; Humans; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases | 1995 |
Paclitaxel (TAXOL): side effects and patient education issues.
Topics: Drug Hypersensitivity; Heart; Humans; Leukopenia; Liver; Nervous System Diseases; Paclitaxel; Patient Education as Topic | 1993 |
Taxol (paclitaxel): a novel anti-microtubule agent with remarkable anti-neoplastic activity.
Topics: Animals; Antineoplastic Agents, Phytogenic; Arrhythmias, Cardiac; Cell Cycle; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Drug Hypersensitivity; Drug Screening Assays, Antitumor; Gastrointestinal Diseases; Humans; Mice; Microtubules; Neoplasms; Neoplasms, Experimental; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Polyethylene Glycols; Taxoids; Tubulin | 1994 |
Overview of Taxol safety.
Topics: Bone Marrow; Cardiovascular Diseases; Drug Hypersensitivity; Humans; Nervous System Diseases; Paclitaxel | 1993 |
Pharmacology and toxicology of Cremophor EL diluent.
Topics: Animals; Drug Hypersensitivity; Glycerol; Humans; Paclitaxel; Pharmaceutical Vehicles; Solvents; Surface-Active Agents | 1994 |
Patient care issues: the management of paclitaxel-related toxicities.
Topics: Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Hypersensitivity; Gastrointestinal Diseases; Humans; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases | 1994 |
Pharmaceutical issues of paclitaxel. Preclinical pharmacology and phase I clinical trials.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Drug Hypersensitivity; Drug Screening Assays, Antitumor; Humans; Neoplasms; Neutropenia; Paclitaxel | 1994 |
The taxoids: paclitaxel and docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Drug Hypersensitivity; Drug Interactions; Female; Humans; Lung Neoplasms; Ovarian Neoplasms; Paclitaxel; Taxoids | 1994 |
Clinical toxicities encountered with paclitaxel (Taxol).
Topics: Alopecia; Arrhythmias, Cardiac; Brain Diseases; Clinical Trials as Topic; Drug Administration Schedule; Drug Hypersensitivity; Gastrointestinal Diseases; Humans; Immunoglobulin E; Models, Biological; Muscular Diseases; Neoplasms; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Risk Factors | 1993 |
Current dosage and schedule issues in the development of paclitaxel (Taxol).
Topics: Animals; Bone Marrow Diseases; Clinical Trials as Topic; Dogs; Dose-Response Relationship, Drug; Drug Evaluation; Drug Evaluation, Preclinical; Drug Hypersensitivity; Humans; Mice; Microtubules; Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Rats; Time Factors | 1993 |
Combined-modality therapy for advanced non-small cell lung cancer: paclitaxel and thoracic irradiation.
Topics: Ambulatory Care; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Hypersensitivity; Esophagitis; Follow-Up Studies; Humans; Infusions, Intravenous; Lung Neoplasms; Neutropenia; Paclitaxel; Premedication; Radiation Pneumonitis; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy, High-Energy; Remission Induction | 1995 |
Case report of anaphylaxis from cisplatin/paclitaxel and a review of their hypersensitivity reaction profiles.
Topics: Aged; Anaphylaxis; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Hypersensitivity; Fatal Outcome; Humans; Laryngeal Neoplasms; Lung Neoplasms; Male; Paclitaxel; Respiratory Insufficiency; Vocal Cords | 1997 |
[Paclitaxel (taxol): a review of its antitumor activity and toxicity in clinical studies].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Hypersensitivity; Female; Humans; Neoplasms; Neutropenia; Ovarian Neoplasms; Paclitaxel | 1998 |
Acute hypersensitivity reactions to chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Cisplatin; Drug Hypersensitivity; Female; Humans; Middle Aged; Oncology Nursing; Ovarian Neoplasms; Paclitaxel | 1999 |
Hypersensitivity reactions in ovarian cancer patients receiving paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Drug Hypersensitivity; Female; Humans; Ovarian Neoplasms; Paclitaxel; Retrospective Studies | 1999 |
[Paclitaxel for treatment of advanced breast cancers].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Cardiac; Breast Neoplasms; Clinical Trials as Topic; Doxorubicin; Drug Hypersensitivity; Female; Humans; Paclitaxel; Trastuzumab | 2000 |
Docetaxel as an alternative to paclitaxel after acute hypersensitivity reactions.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Drug Hypersensitivity; Female; Humans; Lung Neoplasms; Middle Aged; Ovarian Neoplasms; Paclitaxel; Taxoids | 2000 |
Sequential chemo- and radiochemotherapy with weekly paclitaxel (Taxol) and 3D-conformal radiotherapy of stage III inoperable non-small cell lung cancer. Results of a dose escalation study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cohort Studies; Combined Modality Therapy; Disease-Free Survival; Drug Hypersensitivity; Esophagitis; Humans; Leukopenia; Life Tables; Lung Neoplasms; Maximum Tolerated Dose; Nausea; Neoplasm Staging; Paclitaxel; Prospective Studies; Radiation Injuries; Radiation Pneumonitis; Radiotherapy, Conformal; Remission Induction; Survival Analysis; Survival Rate; Treatment Outcome; Vomiting | 2001 |
Role of formulation vehicles in taxane pharmacology.
Topics: Animals; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chemistry, Pharmaceutical; Cyclosporine; Drug Hypersensitivity; Drug Resistance, Multiple; Glycerol; Humans; Micelles; Neoplasms; Nervous System Diseases; Paclitaxel; Polysorbates; Surface-Active Agents | 2001 |
Prophylaxis for paclitaxel hypersensitivity reactions.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Dexamethasone; Drug Hypersensitivity; Humans; Injections, Intravenous; Paclitaxel; Premedication | 2001 |
Prevention and management of antineoplastic-induced hypersensitivity reactions.
Topics: Antineoplastic Agents; Asparaginase; Docetaxel; Drug Hypersensitivity; Humans; Neoplasms; Organoplatinum Compounds; Paclitaxel; Podophyllotoxin; Taxoids | 2001 |
Hypersensitivity reactions.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Asparaginase; Aziridines; Benzoquinones; Bleomycin; Chlorambucil; Cisplatin; Cyclophosphamide; Cytarabine; Dacarbazine; Drug Hypersensitivity; Etoposide; Fluorouracil; Humans; Ifosfamide; Melphalan; Methotrexate; Mitomycins; Neoplasms; Paclitaxel; Pentostatin; Procarbazine; Teniposide | 1992 |
51 trial(s) available for paclitaxel and Allergy, Drug
| Article | Year |
|---|---|
Efficacy of Premedication Protocol without Ranitidine for Taxane Regimen: A Multicenter Non-Randomized Historical Controlled Study.
Topics: Antineoplastic Agents, Phytogenic; Cohort Studies; Drug Hypersensitivity; Historically Controlled Study; Humans; Multicenter Studies as Topic; Paclitaxel; Premedication; Ranitidine; Taxoids | 2022 |
The added value of H
Topics: Adult; Aged; Aged, 80 and over; Chemoprevention; Clemastine; Dexamethasone; Drug Hypersensitivity; Drug Therapy, Combination; Equivalence Trials as Topic; Female; Histamine H2 Antagonists; Humans; Infusions, Intravenous; Male; Medical Futility; Middle Aged; Neoplasms; Netherlands; Paclitaxel; Premedication; Ranitidine; Severity of Illness Index; Treatment Outcome | 2021 |
Randomized, Controlled Trial of Dexamethasone Versus Dexamethasone Plus Hydrocortisone as Prophylaxis for Hypersensitivity Reactions Due to Paclitaxel Treatment for Gynecologic Cancer.
Topics: Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Hypersensitivity; Female; Genital Neoplasms, Female; Humans; Hydrocortisone; Middle Aged; Organoplatinum Compounds; Paclitaxel | 2017 |
The feasibility of dexamethasone omission in weekly paclitaxel treatment for breast cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dexamethasone; Diphenhydramine; Drug Administration Schedule; Drug Hypersensitivity; Drug Substitution; Feasibility Studies; Female; Humans; Incidence; Infusions, Intravenous; Middle Aged; Paclitaxel; Premedication; Prospective Studies; Quality of Life | 2019 |
Role of Skin Tests in the Diagnosis of Immediate Hypersensitivity Reactions to Taxanes: Results of a Multicenter Study.
Topics: Adult; Aged; Antineoplastic Agents; Docetaxel; Drug Hypersensitivity; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Skin Tests | 2019 |
Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Docetaxel; Drug Hypersensitivity; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids | 2013 |
Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclit
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carboplatin; Dexamethasone; Double-Blind Method; Drug Hypersensitivity; Drug Therapy, Combination; Female; Genital Neoplasms, Female; Humans; Middle Aged; Morpholines; Nausea; Paclitaxel; Remission Induction; Serotonin 5-HT3 Receptor Antagonists; Vomiting; Young Adult | 2016 |
Intravenous versus oral dexamethasone for prophylaxis of paclitaxel-associated hypersensitivity reaction in patients with primary ovarian, fallopian tube and peritoneal cancer: A double-blind randomized controlled trial.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Animals; Antineoplastic Agents, Phytogenic; Dexamethasone; Double-Blind Method; Drug Hypersensitivity; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2016 |
[Evaluation of short-time premedication with d-chlorpheniramine maleate injection for paclitaxel-induced hypersensitivity reaction].
Topics: Adult; Aged; Aged, 80 and over; Chlorpheniramine; Drug Hypersensitivity; Female; Humans; Injections; Male; Middle Aged; Neoplasms; Paclitaxel; Premedication; Time Factors | 2008 |
Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Doxorubicin; Drug Hypersensitivity; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols | 2011 |
Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cimetidine; Clemastine; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Drug Hypersensitivity; Drug Resistance, Neoplasm; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Injections, Intravenous; Life Tables; Middle Aged; Muscular Diseases; Nervous System Diseases; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Premedication; Salvage Therapy; Survival Analysis; Treatment Outcome | 2002 |
Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses.
Topics: Adult; Aged; Carboplatin; Desensitization, Immunologic; Drug Hypersensitivity; Female; Humans; Inpatients; Male; Middle Aged; Neoplasms; Outpatients; Paclitaxel; Skin Tests | 2005 |
Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer.
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Breast Neoplasms; Disease Progression; Drug Hypersensitivity; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel | 2005 |
A randomized trial assessing the utility of a test-dose program with taxanes.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Cost Control; Docetaxel; Drug Hypersensitivity; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 2005 |
Prophylactic effect of pemirolast, an antiallergic agent, against hypersensitivity reactions to paclitaxel in patients with ovarian cancer.
Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Hypersensitivity; Female; Histamine Antagonists; Humans; Ovarian Neoplasms; Paclitaxel; Placebos; Pyridines; Pyrimidinones | 2006 |
Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Drug Hypersensitivity; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Polyglutamic Acid; Taxoids | 2007 |
Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Drug Hypersensitivity; Esophageal Neoplasms; Esophagitis; Facial Dermatoses; Feasibility Studies; Female; Humans; Male; Middle Aged; Paclitaxel; Stomach Neoplasms | 2008 |
Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer.
Topics: Aged; Bone Marrow Diseases; Drug Administration Schedule; Drug Hypersensitivity; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Male; Middle Aged; Musculoskeletal Diseases; Neoplasms; Paclitaxel; Peripheral Nervous System Diseases | 1994 |
A phase I trial of 3-hour infusions of paclitaxel (Taxol) with or without granulocyte colony-stimulating factor.
Topics: Drug Hypersensitivity; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Male; Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Time Factors | 1994 |
Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Hypersensitivity; Female; Humans; Male; Melanoma; Middle Aged; Paclitaxel; Taxoids | 1994 |
Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Drug Hypersensitivity; Drug Resistance; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Remission Induction; Survival Rate; Taxoids | 1995 |
Docetaxel in advanced renal carcinoma. A phase II trial of the National Cancer Institute of Canada Clinical Trials Group.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Hypersensitivity; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids | 1994 |
Paclitaxel administered by 1-hour infusion. Preliminary results of a phase I/II trial comparing two schedules.
Topics: Adult; Aged; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cimetidine; Dexamethasone; Diphenhydramine; Drug Administration Schedule; Drug Hypersensitivity; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasms; Ovarian Neoplasms; Paclitaxel; Premedication; Prospective Studies; Remission Induction | 1994 |
Phase II trial of docetaxel (Taxotere) in metastatic colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Antineoplastic Agents, Phytogenic; Colorectal Neoplasms; Docetaxel; Drug Administration Schedule; Drug Eruptions; Drug Hypersensitivity; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids | 1994 |
Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Hypersensitivity; Esophagitis; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Radiotherapy Dosage | 1994 |
Successful re-treatment with taxol after major hypersensitivity reactions.
Topics: Aged; Dexamethasone; Diphenhydramine; Drug Hypersensitivity; Female; Histamine H1 Antagonists; Histamine H2 Antagonists; Humans; Middle Aged; Paclitaxel; Premedication | 1993 |
Coping with toxicities of docetaxel (Taxotere).
Topics: Antineoplastic Agents, Phytogenic; Cetirizine; Docetaxel; Drug Hypersensitivity; Edema; Humans; Ketotifen; Methylprednisolone; Paclitaxel; Skin Diseases; Taxoids | 1993 |
Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Disease-Free Survival; Drug Hypersensitivity; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Nervous System Diseases; Paclitaxel; Survival Rate; Treatment Outcome | 1996 |
Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cimetidine; Dexamethasone; Diphenhydramine; Docetaxel; Drug Administration Schedule; Drug Hypersensitivity; Edema; Female; Humans; Injections, Intravenous; Leukopenia; Middle Aged; Neoplasm Metastasis; Paclitaxel; Premedication; Taxoids | 1996 |
Phase I study of paclitaxel in combination with cyclophosphamide and granulocyte colony-stimulating factor in metastatic breast cancer patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Breast Neoplasms; Cyclophosphamide; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Hypersensitivity; Equipment Failure; Erythrocyte Transfusion; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hematuria; Home Infusion Therapy; Humans; Mesna; Middle Aged; Neoplasm Metastasis; Paclitaxel | 1996 |
Paclitaxel premedication regimens.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cimetidine; Dexamethasone; Drug Hypersensitivity; Female; Glucocorticoids; Histamine H2 Antagonists; Humans; Infusions, Intravenous; Ovarian Neoplasms; Paclitaxel; Premedication; Ranitidine | 1996 |
Phase I study of paclitaxel by three-hour infusion: hypotension just after infusion is one of the major dose-limiting toxicities.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents, Phytogenic; Chemical and Drug Induced Liver Injury; Drug Hypersensitivity; Female; Histamine Antagonists; Humans; Hypotension; Immunosuppressive Agents; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Paclitaxel; Pain; Peripheral Nervous System Diseases; Premedication | 1995 |
Combined-modality therapy for advanced non-small cell lung cancer: paclitaxel and thoracic irradiation.
Topics: Ambulatory Care; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Hypersensitivity; Esophagitis; Follow-Up Studies; Humans; Infusions, Intravenous; Lung Neoplasms; Neutropenia; Paclitaxel; Premedication; Radiation Pneumonitis; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy, High-Energy; Remission Induction | 1995 |
[Early phase II study of BMS-181339 (paclitaxel) in patients with non-small cell lung cancer. BMS-181339 Non-Small Cell Lung Cancer Study Group].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Hypersensitivity; Female; Humans; Infusions, Intravenous; Japan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Remission Induction; Taxoids | 1996 |
Rapid intravenous premedication with dexamethasone prevents hypersensitivity reactions to paclitaxel.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Dexamethasone; Drug Administration Schedule; Drug Hypersensitivity; Female; Glucocorticoids; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Paclitaxel | 1996 |
Paclitaxel and simultaneous radiation in locally advanced stage IIIA/B non-small cell lung cancer: a clinical phase I study.
Topics: Adult; Aged; Anti-Allergic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Clemastine; Combined Modality Therapy; Dexamethasone; Drug Administration Schedule; Drug Hypersensitivity; Drug Tolerance; Female; Histamine H2 Antagonists; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Premedication; Radiation-Sensitizing Agents; Radiotherapy Dosage; Ranitidine; Remission Induction; Treatment Outcome | 1996 |
Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Transitional Cell; Docetaxel; Drug Hypersensitivity; Female; Humans; Male; Middle Aged; Paclitaxel; Remission Induction; Survival Analysis; Taxoids; Urologic Neoplasms | 1997 |
Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Cimetidine; Dexamethasone; Diphenhydramine; Drug Administration Schedule; Drug Hypersensitivity; Female; Glucocorticoids; Histamine H1 Antagonists; Histamine H2 Antagonists; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Paclitaxel; Ranitidine; Retrospective Studies | 1997 |
Paclitaxel in untreated FIGO stage III suboptimally resected ovarian cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Drug Hypersensitivity; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel | 1997 |
Weekly docetaxel and concomitant boost radiotherapy for non-small cell lung cancer. A phase I/II dose escalation trial.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Hypersensitivity; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy; Taxoids; Treatment Outcome | 1998 |
Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion.
Topics: Agranulocytosis; Antineoplastic Agents, Phytogenic; Dexamethasone; Diphenhydramine; Dose-Response Relationship, Drug; Drug Hypersensitivity; Histamine H1 Antagonists; Histamine H2 Antagonists; Humans; Infusions, Intravenous; Leukocyte Count; Neoplasms; Paclitaxel; Ranitidine; Time Factors | 1995 |
Expanded phase II trial of paclitaxel in metastatic breast cancer: a Southwest Oncology Group study.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Hypersensitivity; Female; Gastrointestinal Diseases; Heart Diseases; Hematologic Diseases; Humans; Middle Aged; Neuromuscular Diseases; Paclitaxel; Pain Measurement; Palliative Care; Survival Analysis; Treatment Failure | 1998 |
Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center.
Topics: Adult; Aged; Aged, 80 and over; Clinical Protocols; Desensitization, Immunologic; Dexamethasone; Diphenhydramine; Drug Hypersensitivity; Drug Therapy, Combination; Famotidine; Female; Genital Neoplasms, Female; Glucocorticoids; Histamine H1 Antagonists; Histamine H2 Antagonists; Humans; Middle Aged; Paclitaxel; Premedication | 2000 |
Successful rechallenge with taxanes following prophylactic ketotifen in patients who had developed severe hypersensitivity reactions.
Topics: Adult; Aged; Anti-Allergic Agents; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Hypersensitivity; Female; Humans; Ketotifen; Male; Middle Aged; Neoplasms; Paclitaxel; Pilot Projects; Taxoids | 2000 |
Phase I trial and pharmacological study of a 3-hour paclitaxel infusion in children with refractory solid tumours: a SFOP study.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Child; Child, Preschool; Drug Hypersensitivity; Ethanol; Female; Humans; Infant; Infusions, Intravenous; Male; Maximum Tolerated Dose; Neoplasm, Residual; Neurotoxicity Syndromes; Paclitaxel; Polyethylene Glycols; Solvents | 2001 |
Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Docetaxel; Drug Hypersensitivity; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids | 2001 |
Sequential chemo- and radiochemotherapy with weekly paclitaxel (Taxol) and 3D-conformal radiotherapy of stage III inoperable non-small cell lung cancer. Results of a dose escalation study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cohort Studies; Combined Modality Therapy; Disease-Free Survival; Drug Hypersensitivity; Esophagitis; Humans; Leukopenia; Life Tables; Lung Neoplasms; Maximum Tolerated Dose; Nausea; Neoplasm Staging; Paclitaxel; Prospective Studies; Radiation Injuries; Radiation Pneumonitis; Radiotherapy, Conformal; Remission Induction; Survival Analysis; Survival Rate; Treatment Outcome; Vomiting | 2001 |
Dose reduction of steroid premedication for paclitaxel: no increase of hypersensitivity reactions.
Topics: Adult; Aged; Aged, 80 and over; Anaphylaxis; Clemastine; Dexamethasone; Dose-Response Relationship, Drug; Drug Hypersensitivity; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Paclitaxel; Premedication; Ranitidine; Treatment Outcome | 2001 |
Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Drug Hypersensitivity; Female; Humans; Male; Middle Aged; Paclitaxel; Premedication; Stomach Neoplasms; Survival Analysis | 2001 |
Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Hypersensitivity; Female; Humans; Leukopenia; Middle Aged; Nausea; Neutropenia; Ovarian Neoplasms; Paclitaxel; Survival Rate; Vomiting | 2002 |
Phase I trial of taxol given as a 3-hour infusion every 21 days.
Topics: Adult; Aged; Alkaloids; Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Drug Administration Schedule; Drug Evaluation; Drug Hypersensitivity; Female; Humans; Hypersensitivity, Immediate; Infusions, Parenteral; Male; Middle Aged; Neoplasms; Paclitaxel | 1986 |
128 other study(ies) available for paclitaxel and Allergy, Drug
| Article | Year |
|---|---|
Hypersensitivity Reactions: Practice Recommendations for Paclitaxel Administration.
Topics: Antineoplastic Agents, Phytogenic; Drug Hypersensitivity; Humans; Paclitaxel; Retrospective Studies | 2021 |
Risk factors for and prognosis of carboplatin-related hypersensitivity in patients with epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Drug Hypersensitivity; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Risk Factors | 2022 |
Complete metabolic response after carboplatin desensitization in Peritoneal Carcinomatosis.
Topics: Antineoplastic Agents; Carboplatin; Desensitization, Immunologic; Drug Hypersensitivity; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Positron Emission Tomography Computed Tomography | 2022 |
Histamine-2 (H
Topics: Antineoplastic Agents, Phytogenic; Cohort Studies; Dexamethasone; Drug Hypersensitivity; Histamine; Histamine H1 Antagonists; Histamine H2 Antagonists; Humans; Paclitaxel; Premedication; Prospective Studies | 2022 |
Outcomes of a Undiluted, One-Bag Desensitization Protocol for Chemotherapeutic Agents.
Topics: Adult; Antineoplastic Agents; Carboplatin; Desensitization, Immunologic; Drug Hypersensitivity; Humans; Observational Studies as Topic; Oxaliplatin; Paclitaxel | 2023 |
Ranitidine and the incidence of hypersensitivity reactions to paclitaxel: A retrospective cohort study.
Topics: Antineoplastic Agents, Phytogenic; Dexamethasone; Drug Hypersensitivity; Humans; Incidence; Paclitaxel; Ranitidine; Retrospective Studies | 2022 |
Taxanes hypersensitivity is not a risk factor for severe reactions to SARS-CoV-2 vaccines.
Topics: Anaphylaxis; COVID-19; COVID-19 Vaccines; Drug Hypersensitivity; Humans; Paclitaxel; Polysorbates; Risk Factors; SARS-CoV-2; Taxoids | 2023 |
A Three-Step Taxane Titration Protocol Decreases Hypersensitivity Reactions During First and Second Exposures.
Topics: Docetaxel; Drug Hypersensitivity; Epinephrine; Humans; Paclitaxel; Prospective Studies; Taxoids | 2023 |
Impact of histamine-2 antagonist shortage on the incidence of hypersensitivity reactions to paclitaxel: a reconsideration of premedication protocols in France (PACLIREACT Study).
Topics: Antineoplastic Agents, Phytogenic; Dexamethasone; Drug Hypersensitivity; Histamine; Histamine Antagonists; Humans; Hypersensitivity; Incidence; Paclitaxel; Premedication; Ranitidine; Retrospective Studies | 2023 |
Hypersensitivity Reaction and Rapid Drug Desensitization with Chemotherapeutics: A Tertiary Reference Center Experiences.
Topics: Anaphylaxis; Antineoplastic Agents; Desensitization, Immunologic; Drug Hypersensitivity; Female; Humans; Male; Oxaliplatin; Paclitaxel; Skin Tests | 2023 |
The Involvement of the RhoA/ROCK Signaling Pathway in Hypersensitivity Reactions Induced by Paclitaxel Injection.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biopsy; Complement Activation; Complement System Proteins; Disease Models, Animal; Drug Hypersensitivity; Female; Histamine Release; Male; Mice; Paclitaxel; rho-Associated Kinases; rhoA GTP-Binding Protein; Signal Transduction | 2019 |
A One-Bag Rapid Desensitization Protocol for Paclitaxel Hypersensitivity: A Noninferior Alternative to a Multi-Bag Rapid Desensitization Protocol.
Topics: Antineoplastic Agents; Desensitization, Immunologic; Drug Hypersensitivity; Humans; Incidence; Paclitaxel; Retrospective Studies | 2020 |
Rapid desensitization to antineoplastic drugs in an outpatient immunoallergology clinic: Outcomes and risk factors.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Bridged-Ring Compounds; Cetuximab; Desensitization, Immunologic; Drug Hypersensitivity; Female; Humans; Immunoglobulin E; Male; Middle Aged; Neoplasms; Outpatients; Paclitaxel; Portugal; Retrospective Studies; Risk Factors; Skin Tests; Taxoids; Trastuzumab; Young Adult | 2020 |
Kounis Syndrome after Angioplasty of the Superficial Femoral Artery with Paclitaxel-Coated Balloon.
Topics: Aged; Anaphylaxis; Angioplasty, Balloon; Cardiovascular Agents; Constriction, Pathologic; Drug Hypersensitivity; Female; Femoral Artery; Humans; Kounis Syndrome; Paclitaxel; Peripheral Arterial Disease; Treatment Outcome; Vascular Access Devices | 2020 |
Unsuccessful Desensitization to Paclitaxel in a Patient With High Basophil Sensitivity.
Topics: Antineoplastic Agents; Basophil Degranulation Test; Basophils; Breast Neoplasms; Desensitization, Immunologic; Drug Hypersensitivity; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Middle Aged; Paclitaxel; Treatment Failure | 2021 |
Characteristics of immediate hypersensitivity reaction to paclitaxel-based chemotherapy in gynecologic cancer patients.
Topics: Dexamethasone; Drug Hypersensitivity; Female; Genital Neoplasms, Female; Humans; Hypersensitivity, Immediate; Middle Aged; Paclitaxel; Retrospective Studies | 2023 |
Mast cells activation and high blood tryptase levels due to paclitaxel administration. Is Cremophor EL the culprit?: A case report.
Topics: Aged; Drug Hypersensitivity; Glycerol; Humans; Male; Mast Cells; Paclitaxel; Tryptases; Urologic Neoplasms | 2020 |
Comparison of subsequent infusion hypersensitivity reactions to paclitaxel using two different infusion strategies.
Topics: Adult; Aged; Drug Hypersensitivity; Female; Humans; Incidence; Male; Middle Aged; Paclitaxel; Retrospective Studies | 2021 |
Comparative study of oral and IV dexamethasone premedication in the prevention of docetaxel induced allergic reactions.
Topics: Dexamethasone; Docetaxel; Drug Hypersensitivity; Humans; Paclitaxel; Premedication; Retrospective Studies | 2022 |
No need for H
Topics: Drug Hypersensitivity; Histamine H2 Antagonists; Humans; Paclitaxel; Premedication; Ranitidine | 2021 |
Hypersensitivity reactions to paclitaxel: The Mexican experience of rapid desensitization.
Topics: Adult; Breast Neoplasms; Desensitization, Immunologic; Drug Hypersensitivity; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hypersensitivity, Immediate; Male; Paclitaxel; Retrospective Studies | 2022 |
Anaphylactic Reactions With 3 Nonrelated Drugs (Gadoteridol, Paclitaxel, Bevacizumab) in a Patient With Severe Comorbidities.
Topics: Anaphylaxis; Bevacizumab; Drug Hypersensitivity; Gadolinium; Heterocyclic Compounds; Humans; Organometallic Compounds; Paclitaxel | 2022 |
Do Steroids Matter? A Retrospective Review of Premedication for Taxane Chemotherapy and Hypersensitivity Reactions.
Topics: Antineoplastic Agents, Phytogenic; California; Dexamethasone; Docetaxel; Drug Hypersensitivity; Drug Prescriptions; Drug Utilization; Electronic Health Records; Female; Humans; Male; Paclitaxel; Practice Patterns, Physicians'; Premedication; Retrospective Studies; Risk Assessment; Risk Factors; Steroids; Time Factors; Treatment Outcome | 2021 |
Is there any predictor for hypersensitivity reactions in gynecologic cancer patients treated with paclitaxel-based therapy?
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Drug Hypersensitivity; Drugs, Generic; Female; Genital Neoplasms, Female; Humans; Incidence; Middle Aged; Multivariate Analysis; Paclitaxel; Retrospective Studies; Risk Factors; Time Factors; Young Adult | 2017 |
Universal tolerance of nab-paclitaxel for gynecologic malignancies in patients with prior taxane hypersensitivity reactions.
Topics: Adult; Aged; Albumins; Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cisplatin; Deoxycytidine; Docetaxel; Drug Hypersensitivity; Female; Gemcitabine; Genital Neoplasms, Female; Humans; Middle Aged; Nervous System Diseases; Neutropenia; Paclitaxel; Retreatment; Retrospective Studies; Taxoids; Thrombocytopenia | 2017 |
Incidence of infusion hypersensitivity reaction after withholding dexamethasone premedication in early breast cancer patients not experiencing two previous cycles of infusion hypersensitivity reaction for weekly paclitaxel chemotherapy.
Topics: Adult; Aged; Breast Neoplasms; Bridged-Ring Compounds; Cohort Studies; Dexamethasone; Drug Hypersensitivity; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Incidence; Middle Aged; Paclitaxel; Premedication; Retrospective Studies; Taxoids | 2018 |
Ionic-Liquid-Based Paclitaxel Preparation: A New Potential Formulation for Cancer Treatment.
Topics: Antineoplastic Agents, Phytogenic; Drug Compounding; Drug Delivery Systems; Drug Hypersensitivity; Excipients; Glycerol; HeLa Cells; Humans; Ionic Liquids; Neoplasms; Paclitaxel; Solubility | 2018 |
Retrospective evaluation of a rechallenge protocol in patients experiencing hypersensitivity reactions with prior chemotherapy in a tertiary hospital.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Docetaxel; Drug Hypersensitivity; Female; Humans; Male; Middle Aged; Oxaliplatin; Paclitaxel; Premedication; Retrospective Studies; Tertiary Care Centers | 2019 |
Cetirizine versus diphenhydramine in the prevention of chemotherapy-related hypersensitivity reactions.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Agents, Phytogenic; Cetirizine; Cetuximab; Diphenhydramine; Drug Hypersensitivity; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Premedication; Prospective Studies; Retrospective Studies; Rituximab | 2019 |
A cohort study of hypersensitivity reaction in patients with epithelial ovarian cancer treated with carboplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cohort Studies; Dose-Response Relationship, Drug; Drug Hypersensitivity; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Progression-Free Survival; Retrospective Studies | 2019 |
In vivo biocompatibility, pharmacokinetics, antitumor efficacy, and hypersensitivity evaluation of ionic liquid-mediated paclitaxel formulations.
Topics: Administration, Intravenous; Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Drug Delivery Systems; Drug Hypersensitivity; Female; Glycerol; Ionic Liquids; Melanoma; Mice, Inbred C57BL; Paclitaxel; Skin Neoplasms | 2019 |
Intravenous versus oral dexamethasone premedication in preventing Paclitaxel infusion hypersensitivity reactions in gynecological malignancies.
Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Dexamethasone; Drug Hypersensitivity; Female; Follow-Up Studies; Genital Neoplasms, Female; Humans; Injections, Intravenous; Paclitaxel; Premedication; Prognosis | 2013 |
[Hypersensitivity reactions to carboplatin and paclitaxel - our five-years experiences].
Topics: Adult; Antineoplastic Agents; Carboplatin; Czech Republic; Drug Hypersensitivity; Female; Follow-Up Studies; Humans; Incidence; Male; Paclitaxel; Retrospective Studies; Time Factors | 2013 |
[A patient with paclitaxel hypersensitivity treated with nab-paclitaxel].
Topics: Albumins; Antineoplastic Agents, Phytogenic; Dexamethasone; Drug Hypersensitivity; Fatal Outcome; Humans; Liver Neoplasms; Male; Middle Aged; Paclitaxel; Premedication; Stomach Neoplasms | 2014 |
Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dexamethasone; Diphenhydramine; Drug Administration Schedule; Drug Hypersensitivity; Famotidine; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Staging; Paclitaxel; Premedication; Prospective Studies; Retrospective Studies | 2015 |
[Safe treatment of lung squamous cell carcinoma with nanoparticle albumin-bound Paclitaxel in a patient with a previous hypersensitivity reaction after docetaxel administration].
Topics: Albumins; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Docetaxel; Drug Hypersensitivity; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids | 2015 |
[Ovarian cancer: TC therapy].
Topics: Antineoplastic Agents; Bone Marrow; Carboplatin; Drug Hypersensitivity; Female; Humans; Ovarian Neoplasms; Paclitaxel | 2015 |
Utility of delayed reading of intradermal test in carboplatin-induced drug hypersensitivity.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Drug Hypersensitivity; Female; Humans; Hypersensitivity, Delayed; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Skin Tests | 2015 |
Risk stratification and skin testing to guide re-exposure in taxane-induced hypersensitivity reactions.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Desensitization, Immunologic; Docetaxel; Drug Hypersensitivity; Female; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Paclitaxel; Retrospective Studies; Risk Assessment; Severity of Illness Index; Skin Tests; Taxoids; Treatment Outcome | 2016 |
Paclitaxel pre-medication: A comparison of two steroid pre-medication protocols.
Topics: Adult; Aged; Aged, 80 and over; Dexamethasone; Drug Hypersensitivity; Female; Glucocorticoids; Humans; Middle Aged; Neoplasms; Paclitaxel; Premedication; Retrospective Studies | 2017 |
Acute hypersensitivity reaction to femoral drug-coated balloons.
Topics: Acute Disease; Aged; Amputation, Surgical; Anaphylaxis; Angiography; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Drug Hypersensitivity; Femoral Artery; Humans; Male; Paclitaxel; Peripheral Arterial Disease; Treatment Outcome; Vascular Access Devices | 2017 |
Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Doxorubicin; Drug Hypersensitivity; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Retrospective Studies | 2017 |
Drug-eluting coronary stents: hypersensitivity reactions to paclitaxel. A case report.
Topics: Aged; Anaphylaxis; Anti-Allergic Agents; Cardiovascular Agents; Coronary Disease; Coronary Restenosis; Drug Hypersensitivity; Drug-Eluting Stents; Histamine H1 Antagonists; Humans; Male; Paclitaxel; Treatment Outcome | 2009 |
Retrospective evaluation of weekly paclitaxel hypersensitivity reactions reported utilizing an electronic medical record system at a tertiary cancer center.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Drug Hypersensitivity; Humans; Infusions, Intravenous; Logistic Models; Medical Records Systems, Computerized; Paclitaxel; Premedication; Retrospective Studies | 2009 |
Drug-eluting coronary stents: hypersensitivity reactions to paclitaxel and the risk of Kounis syndrome.
Topics: Acute Coronary Syndrome; Drug Hypersensitivity; Drug-Eluting Stents; Humans; Paclitaxel | 2009 |
Intimal proliferation and restenosis in paclitaxel-eluting stents with aminoparylene as carrier substance in swines.
Topics: Animals; Cell Proliferation; Chromium Alloys; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Coronary Vessels; Disease Models, Animal; Drug Hypersensitivity; Drug-Eluting Stents; Incidence; Metals; Paclitaxel; Polymers; Stents; Swine; Tunica Intima; Xylenes | 2009 |
Pemetrexed-induced pneumonitis: a case report.
Topics: Adrenal Cortex Hormones; Aged; Anti-Infective Agents; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Ciprofloxacin; Cisplatin; Drug Hypersensitivity; Drug Therapy, Combination; Dyspnea; Erythema; Glutamates; Guanine; Humans; Lung; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Paclitaxel; Pemetrexed; Pneumonia; Pulmonary Fibrosis; Recovery of Function; Solitary Pulmonary Nodule | 2009 |
Abraxane for the treatment of gynecologic cancer patients with severe hypersensitivity reactions to paclitaxel.
Topics: Adenocarcinoma; Aged, 80 and over; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents; Drug Hypersensitivity; Female; Genital Neoplasms, Female; Humans; Middle Aged; Paclitaxel; Treatment Outcome | 2009 |
Letter to the editor. Paclitaxel-Induced ST-segment elevations: A manifestation of allergic acute coronary syndrome (Kounis Syndrome) [corrected].
Topics: Acute Coronary Syndrome; Antineoplastic Agents, Phytogenic; Coronary Artery Disease; Drug Hypersensitivity; Humans; Paclitaxel; Syndrome | 2009 |
[Administration of premedication with fexofenadine for paclitaxel-induced hypersensitive reactions in breast cancer patients complicated with closed-angle glaucoma].
Topics: Anti-Allergic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Hypersensitivity; Female; Glaucoma, Angle-Closure; Humans; Middle Aged; Paclitaxel; Premedication; Terfenadine | 2010 |
Immunoglobulin E-mediated severe anaphylaxis to paclitaxel.
Topics: Anaphylaxis; Antineoplastic Combined Chemotherapy Protocols; Asthma; Cisplatin; Deoxycytidine; Drug Hypersensitivity; Dyspnea; Epitopes; Female; Gemcitabine; Humans; Hypersensitivity, Immediate; Hypotension; Immunoglobulin E; Middle Aged; Neoplasms; Paclitaxel; Pulmonary Atelectasis; Remission Induction; Skin Tests | 2010 |
Association of CYP1B1 with hypersensitivity induced by taxane therapy in breast cancer patients.
Topics: Aged; Antineoplastic Agents, Phytogenic; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Breast Neoplasms, Male; Chemotherapy, Adjuvant; Chi-Square Distribution; Cytochrome P-450 CYP1B1; Cytochrome P-450 CYP2C8; Cytochrome P-450 Enzyme System; Docetaxel; Drug Hypersensitivity; Female; Gene Frequency; Genetic Predisposition to Disease; Humans; Italy; Logistic Models; Male; Middle Aged; Neoadjuvant Therapy; Odds Ratio; Paclitaxel; Phenotype; Polymorphism, Single Nucleotide; Retrospective Studies; Risk Assessment; Risk Factors; Taxoids; Treatment Outcome | 2010 |
[Comparison of hypersensitivity to branded and generic paclitaxel injections in rats].
Topics: Animals; Antineoplastic Agents, Phytogenic; Drug Hypersensitivity; Drugs, Generic; Hydrogen-Ion Concentration; Injections; Male; Osmotic Pressure; Paclitaxel; Pulmonary Edema; Rats; Rats, Sprague-Dawley | 2011 |
Hypersensitivity reactions to anticancer agents: data mining of the public version of the FDA adverse event reporting system, AERS.
Topics: Adverse Drug Reaction Reporting Systems; Antineoplastic Agents; Asparaginase; Bayes Theorem; Data Mining; Docetaxel; Drug Hypersensitivity; Etoposide; Humans; Paclitaxel; Pharmacovigilance; Procarbazine; Prognosis; Taxoids; Teniposide; United States; United States Food and Drug Administration | 2011 |
Feasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dexamethasone; Drug Hypersensitivity; Feasibility Studies; Female; Focus Groups; Glucocorticoids; Histamine Antagonists; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Premedication; United States; Withholding Treatment | 2012 |
Cross-sensitivity between taxanes in patients with breast cancer.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dexamethasone; Docetaxel; Drug Hypersensitivity; Female; Follow-Up Studies; Humans; Middle Aged; Paclitaxel; Premedication; Retrospective Studies; Taxoids; Treatment Outcome | 2011 |
TRPA1 and TRPV4 mediate paclitaxel-induced peripheral neuropathy in mice via a glutathione-sensitive mechanism.
Topics: Acetanilides; Animals; Calcitonin Gene-Related Peptide; Capsaicin; Cold Temperature; Drug Hypersensitivity; Glutathione; Hyperalgesia; In Vitro Techniques; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Morpholines; Paclitaxel; Peripheral Nervous System Diseases; Purines; Pyrroles; Transient Receptor Potential Channels; TRPA1 Cation Channel; TRPV Cation Channels | 2012 |
A search for predictive factors for hypersensitivity reactions to paclitaxel and platinum salts in chemotherapy for gynecologic pelvic neoplasms.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Drug Hypersensitivity; Female; Genital Neoplasms, Female; Humans; Menopause; Middle Aged; Multivariate Analysis; Paclitaxel; Pelvic Neoplasms; Platinum Compounds; Retrospective Studies; Risk Factors | 2012 |
Suspected hypersensitivity reaction following drug-eluting stent implantation. Novel insights with optical coherence tomography.
Topics: Aged; Antineoplastic Agents, Phytogenic; Coronary Restenosis; Drug Hypersensitivity; Drug-Eluting Stents; Female; Humans; Inflammation; Paclitaxel; Tomography, Optical Coherence | 2012 |
Premedication strategy for weekly paclitaxel.
Topics: Administration, Oral; Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Cimetidine; Dexamethasone; Diphenhydramine; Drug Administration Schedule; Drug Hypersensitivity; Drug Therapy, Combination; Female; Histamine H1 Antagonists; Histamine H2 Antagonists; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Retrospective Studies | 2002 |
Hypersensitivity reaction to carboplatin: successful resolution by replacement with cisplatin.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Cisplatin; Diagnosis, Differential; Drug Hypersensitivity; Female; Humans; Paclitaxel; Peritoneal Neoplasms; Skin Tests | 2002 |
[Reinduction of paclitaxel therapy after a successfully treated hypersensitivity reaction].
Topics: Adult; Antineoplastic Agents, Phytogenic; Carcinoma; Drug Eruptions; Drug Hypersensitivity; Female; Humans; Ovarian Neoplasms; Paclitaxel | 2002 |
An alternative paclitaxel microemulsion formulation: hypersensitivity evaluation and pharmacokinetic profile.
Topics: Animals; Antineoplastic Agents, Phytogenic; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Drug Hypersensitivity; Emulsions; Female; Glycerol; Guinea Pigs; Male; Paclitaxel | 2003 |
Hypersensitivity reactions in paclitaxel treatment of ovarian cancer patients.
Topics: Aged; Anaphylaxis; Antineoplastic Agents, Phytogenic; Drug Hypersensitivity; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel | 2002 |
Unknown primary carcinoma: a feasibility assessment of combination chemotherapy with cisplatin and docetaxel.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Diarrhea; Docetaxel; Drug Hypersensitivity; Feasibility Studies; Female; Humans; Male; Middle Aged; Nausea; Neoplasms, Unknown Primary; Neutropenia; Paclitaxel; Patient Compliance; Prospective Studies; Severity of Illness Index; Taxoids; Treatment Outcome; Vomiting | 2003 |
[Paclitaxel hypersensitivity reactions in patients with advanced ovarian carcinoma].
Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Cimetidine; Dexamethasone; Diphenhydramine; Drug Administration Schedule; Drug Hypersensitivity; Drug Therapy, Combination; Female; Glucocorticoids; Histamine H1 Antagonists; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Radiation-Sensitizing Agents; Retrospective Studies; Severity of Illness Index | 2002 |
[Studies on hypersensitivity and pharmacokinetics of paclitaxel microemulsion].
Topics: Animals; Antineoplastic Agents, Phytogenic; Drug Hypersensitivity; Emulsions; Female; Guinea Pigs; Injections, Intravenous; Male; Paclitaxel; Rats | 2003 |
Role of sensory nerve peptides rather than mast cell histamine in paclitaxel hypersensitivity.
Topics: Analysis of Variance; Animals; Biopsy, Needle; Bronchoalveolar Lavage Fluid; Calcitonin Gene-Related Peptide; Disease Models, Animal; Drug Hypersensitivity; Histamine; Immunohistochemistry; Infusions, Intravenous; Male; Mast Cells; Neurokinin A; Neuropeptides; Paclitaxel; Probability; Pulmonary Edema; Rats; Rats, Sprague-Dawley; Sensitivity and Specificity; Sensory Receptor Cells; Substance P | 2004 |
A case of prolonged carboplatin therapy in a patient with carboplatin hypersensitivity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Drug Hypersensitivity; Female; Humans; Middle Aged; Paclitaxel; Peritoneal Neoplasms | 2003 |
Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clemastine; Dexamethasone; Drug Hypersensitivity; Fatal Outcome; Histamine H1 Antagonists; Histamine H2 Antagonists; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Ranitidine; Risk Factors | 2004 |
Pemirolast potently attenuates paclitaxel hypersensitivity reactions through inhibition of the release of sensory neuropeptides in rats.
Topics: Animals; Calcitonin Gene-Related Peptide; Dose-Response Relationship, Drug; Drug Hypersensitivity; Male; Neurokinin A; Neuropeptides; Paclitaxel; Pyridines; Pyrimidinones; Rats; Rats, Sprague-Dawley; Substance P | 2004 |
Eosinophilic ascites: taxol-induced hypersensitivity?
Topics: Antineoplastic Agents, Phytogenic; Ascites; Drug Hypersensitivity; Eosinophilia; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel | 2004 |
Non-allergic nature of docetaxel-induced acute hypersensitivity reactions.
Topics: Administration, Oral; Adult; Blood Pressure; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Drug Hypersensitivity; Female; Gemcitabine; Histamine; Histamine Antagonists; Humans; Hypersensitivity, Immediate; Infusions, Intravenous; Male; Methylprednisolone; Middle Aged; Paclitaxel; Premedication; Serine Endopeptidases; Tachycardia; Taxoids; Time Factors; Tryptases | 2004 |
Similarity and difference in the acute lung injury induced by a radiographic contrast medium and an anticancer agent paclitaxel in rats.
Topics: Animals; Antineoplastic Agents, Phytogenic; Contrast Media; Diagnosis, Differential; Drug Hypersensitivity; Dyspnea; Histamine; Ioxaglic Acid; Lung; Male; Paclitaxel; Pulmonary Edema; Rats; Rats, Sprague-Dawley; Substance P | 2004 |
Carboplatin desensitization.
Topics: Aged; Anaphylaxis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Australia; Carboplatin; Desensitization, Immunologic; Dose-Response Relationship, Drug; Drug Hypersensitivity; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Skin Tests; Women's Health | 2004 |
Advances in taxane therapy for metastatic breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Bone Marrow; Breast Neoplasms; Chemistry, Pharmaceutical; Docetaxel; Drug Hypersensitivity; Heart Diseases; Humans; Nausea; Paclitaxel; Taxoids; Treatment Outcome; Vomiting; Water-Electrolyte Imbalance | 2004 |
Ovariectomy aggravates hypersensitivity reactions to paclitaxel in rats.
Topics: Animals; Antineoplastic Agents, Phytogenic; Drug Hypersensitivity; Enzyme Inhibitors; Estradiol; Female; Isosorbide Dinitrate; Lung; Lung Injury; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitroprusside; Ovariectomy; Paclitaxel; Rats; Rats, Sprague-Dawley; Respiratory Distress Syndrome | 2005 |
Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Desensitization, Immunologic; Docetaxel; Drug Hypersensitivity; Female; Genital Neoplasms, Female; Humans; Middle Aged; Paclitaxel; Taxoids | 2005 |
Albumin-bound paclitaxel (Abraxane) for advanced breast cancer.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Hypersensitivity; Female; Humans; Injections, Intravenous; Paclitaxel; Powders | 2005 |
Tapering and discontinuation of glucocorticoid prophylaxis during prolonged weekly to biweekly paclitaxel administration.
Topics: Adult; Aged; Aged, 80 and over; Anti-Allergic Agents; Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dexamethasone; Diphenhydramine; Drug Administration Schedule; Drug Hypersensitivity; Drug Therapy, Combination; Female; Humans; Middle Aged; Paclitaxel; Prospective Studies | 2005 |
Cross-sensitivity between paclitaxel and docetaxel in a women's cancers program.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Hypersensitivity; Female; Genital Neoplasms, Female; Humans; Paclitaxel; Retrospective Studies; Taxoids | 2006 |
Abraxane in the treatment of ovarian cancer: the absence of hypersensitivity reactions.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents, Phytogenic; Carcinoma, Papillary; Chemotherapy, Adjuvant; Cystadenocarcinoma, Serous; Drug Hypersensitivity; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel | 2006 |
Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project.
Topics: Coronary Vessels; Drug Hypersensitivity; Humans; Paclitaxel; Sirolimus; Stents | 2006 |
Allergic reactions after the implantation of drug-eluting stents: is it the pill or the polymer?
Topics: Coronary Vessels; Drug Hypersensitivity; Humans; Hypersensitivity; Paclitaxel; Sirolimus; Stents | 2006 |
[A case successfully treated by desensitization for paclitaxel-associated hypersensitivity reactions].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Hypersensitivity; Female; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel; Remission Induction | 2007 |
Cross-reactivity between paclitaxel and hazelnut: a case report.
Topics: Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Corylus; Cross Reactions; Diphenhydramine; Drug Hypersensitivity; Female; Histamine H1 Antagonists; Humans; Hydrocortisone; Hypersensitivity, Immediate; Nut Hypersensitivity; Paclitaxel; Plant Proteins; Urinary Bladder Neoplasms | 2007 |
Case report on clopidogrel rash after coronary placement of a paclitaxol-coated stent.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Stenosis; Disease Progression; Drug Hypersensitivity; Drug Therapy, Combination; Exanthema; Humans; Male; Middle Aged; Paclitaxel; Platelet Aggregation Inhibitors; Stents; Ticlopidine; Tubulin Modulators; Urticaria | 2007 |
Preliminary experience with a modified premedication protocol that included intravenous diphenhydramine and calcium bromide for the prophylaxis of paclitaxel-related hypersensitivity reactions.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Bromides; Calcium Compounds; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Diphenhydramine; Drug Hypersensitivity; Female; Humans; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Premedication; Retrospective Studies | 2007 |
Oral premedication for the prevention of hypersensitivity reactions to paclitaxel.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Allergic Agents; Antineoplastic Agents, Phytogenic; Cimetidine; Dexamethasone; Drug Hypersensitivity; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Premedication; Promethazine; Prospective Studies | 2008 |
[A case of effective weekly paclitaxel administration for advanced gastric cancer associated with diabetes mellitus -about the control of blood glucose when dexamethasone for prophylaxis against paclitaxel-associated hypersensitivity reactions to the diab
Topics: Aged; Biomarkers, Tumor; Blood Glucose; Dexamethasone; Diabetes Complications; Drug Hypersensitivity; Female; Humans; Insulin; Paclitaxel; Stomach Neoplasms; Time Factors | 2008 |
Pneumonitis related to treatment with paclitaxel.
Topics: Adult; Breast Neoplasms; Drug Hypersensitivity; Female; Humans; Paclitaxel; Pharmaceutical Vehicles; Pneumonia; Polyethylene Glycols | 1995 |
Paclitaxel-associated hypersensitivity reaction despite high-dose steroids and prolonged infusions.
Topics: Dexamethasone; Drug Hypersensitivity; Female; Humans; Paclitaxel | 1995 |
Paclitaxel rechallenge failure after a major hypersensitivity reaction.
Topics: Adult; Drug Hypersensitivity; Female; Humans; Informed Consent; Paclitaxel | 1993 |
Hypersensitivity reactions from taxol and etoposide.
Topics: Adult; Cross Reactions; Drug Hypersensitivity; Etoposide; Humans; Male; Paclitaxel | 1993 |
[High effectiveness of taxol in advanced ovarian cancer].
Topics: Clinical Trials, Phase II as Topic; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Hypersensitivity; Female; Humans; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Survival Rate | 1993 |
What you need to know about Taxol.
Topics: Adenocarcinoma; Drug Hypersensitivity; Female; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel | 1993 |
Neurotoxicity as a possible manifestation of paclitaxel hypersensitivity reactions.
Topics: Breast Neoplasms; Drug Hypersensitivity; Female; Humans; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases | 1994 |
Low doses of dexamethasone protect against paclitaxel (Taxol)-related hypersensitivity reactions following cycle 1.
Topics: Dexamethasone; Drug Administration Schedule; Drug Hypersensitivity; Humans; Paclitaxel | 1994 |
Nursing considerations in paclitaxel (Taxol) administration.
Topics: Alopecia; Drug Hypersensitivity; Drug Interactions; Drug Therapy; Extravasation of Diagnostic and Therapeutic Materials; Gastrointestinal Diseases; Heart Diseases; Humans; Injections, Intravenous; Mouth Mucosa; Neoplasms; Paclitaxel; Patient Care Planning; Stomatitis | 1993 |
Transient pulmonary infiltrates: a hypersensitivity reaction to paclitaxel.
Topics: Aged; Antineoplastic Agents, Phytogenic; Drug Hypersensitivity; Female; Humans; Male; Middle Aged; Paclitaxel; Respiratory Hypersensitivity | 1996 |
Successful parenteral desensitization to paclitaxel.
Topics: Adult; Antineoplastic Agents, Phytogenic; Cystadenocarcinoma; Desensitization, Immunologic; Drug Hypersensitivity; Female; Humans; Infusions, Parenteral; Ovarian Neoplasms; Paclitaxel | 1996 |
Paclitaxel-induced severe hypersensitivity reaction occurring as a late toxicity.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Hypersensitivity; Humans; Lung Neoplasms; Male; Paclitaxel | 1995 |
Paclitaxel hypersensitivity revisited.
Topics: Antineoplastic Agents, Phytogenic; Desensitization, Immunologic; Drug Hypersensitivity; Fatal Outcome; Female; Humans; Paclitaxel | 1996 |
Pulmonary infiltrates following administration of paclitaxel.
Topics: Aged; Antineoplastic Agents, Phytogenic; Drug Hypersensitivity; Female; Humans; Lung; Lung Diseases; Male; Middle Aged; Paclitaxel; Radiography | 1996 |
Successful docetaxel rechallenge with cromoglycate after major sensitivity reactions.
Topics: Administration, Oral; Anti-Asthmatic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cromolyn Sodium; Docetaxel; Drug Hypersensitivity; Female; Humans; Middle Aged; Paclitaxel; Taxoids | 1996 |
Carboplatin plus paclitaxel in the treatment of gynecologic malignancies: the Cleveland Clinic experience.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; CA-125 Antigen; Carboplatin; Carcinoma; Cause of Death; Drug Hypersensitivity; Endometrial Neoplasms; Female; Fever; Genital Neoplasms, Female; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Peritoneal Neoplasms; Remission Induction; Retrospective Studies; Sepsis; Thrombocytopenia; Treatment Outcome | 1997 |
Simplified regimen for the prevention of paclitaxel-associated hypersensitivity reactions.
Topics: Dexamethasone; Drug Administration Schedule; Drug Hypersensitivity; Humans; Paclitaxel; Retrospective Studies | 1997 |
Intravenous prophylaxis for paclitaxel-related hypersensitivity reactions.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dexamethasone; Drug Hypersensitivity; Female; Humans; Injections, Intravenous; Lung Neoplasms; Ovarian Neoplasms; Paclitaxel; Premedication; Prospective Studies; Retrospective Studies | 1997 |
Taxol hypersensitivity: rapid retreatment is safe and cost effective.
Topics: Adrenal Cortex Hormones; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Hypersensitivity; Female; Histamine Antagonists; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Risk Factors; Time Factors | 1998 |
Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study.
Topics: Antineoplastic Agents, Phytogenic; Complement Activation; Drug Hypersensitivity; Enzyme-Linked Immunosorbent Assay; Glycerol; Humans; In Vitro Techniques; Paclitaxel; Pharmaceutical Vehicles | 1998 |
Single-dose dexamethasone paclitaxel premedication.
Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Dexamethasone; Drug Administration Schedule; Drug Hypersensitivity; Female; Humans; Injections, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 1998 |
[Acute diffuse interstitial pneumopathy following docetaxel (Taxotère). Apropos of 2 cases].
Topics: Aged; Alveolitis, Extrinsic Allergic; Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Hypersensitivity; Glucocorticoids; Humans; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Male; Paclitaxel; Prednisolone; Pulmonary Edema; Taxoids | 1998 |
Elimination of frequent vital sign monitoring in patients receiving paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Drug Hypersensitivity; Humans; Monitoring, Physiologic; Paclitaxel | 1998 |
Paclitaxel hypersensitivity reactions: a role for docetaxel substitution.
Topics: Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Hypersensitivity; Female; Glycerol; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 1998 |
An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Dexamethasone; Diphenhydramine; Drug Administration Schedule; Drug Hypersensitivity; Famotidine; Female; Genital Neoplasms, Female; Histamine Antagonists; Histamine H1 Antagonists; Histamine H2 Antagonists; Humans; Injections, Intravenous; Paclitaxel; Treatment Outcome | 1999 |
Paclitaxel hypersensitivity reactions related to bee-sting allergy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bees; Drug Hypersensitivity; Humans; Insect Bites and Stings; Paclitaxel | 2000 |
Emergency. Chemotherapy-induced hypersensitivity reaction.
Topics: Anti-Allergic Agents; Antineoplastic Agents, Phytogenic; Diphenhydramine; Drug Hypersensitivity; Emergencies; Female; Humans; Methylprednisolone; Middle Aged; Ovarian Neoplasms; Paclitaxel | 2000 |
Use of docetaxel (Taxotere) in patients with paclitaxel (Taxol) hypersensitivity.
Topics: Adult; Antineoplastic Agents, Phytogenic; Carcinoma; Cimetidine; Cystadenocarcinoma; Dexamethasone; Diphenhydramine; Docetaxel; Drug Administration Schedule; Drug Hypersensitivity; Drug Therapy, Combination; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Taxoids | 2000 |
Formation of complement-activating particles in aqueous solutions of Taxol: possible role in hypersensitivity reactions.
Topics: Antineoplastic Agents, Phytogenic; Complement Activation; Complement Membrane Attack Complex; Drug Hypersensitivity; Glycerol; Humans; Immunoglobulins, Intravenous; Micelles; Paclitaxel; Solutions | 2001 |
Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Desensitization, Immunologic; Drug Hypersensitivity; Female; Genital Neoplasms, Female; Humans; Injections, Intravenous; Middle Aged; Paclitaxel; Retrospective Studies | 2001 |
Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bronchial Spasm; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Drug Hypersensitivity; Edema; Erythema; Female; Greece; Humans; Hypertension; Hypotension; Injections, Intraperitoneal; Injections, Intravenous; Ovarian Neoplasms; Paclitaxel; Pruritus; Retrospective Studies; Tachycardia | 2001 |
A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel.
Topics: Administration, Oral; Cohort Studies; Dexamethasone; Diphenhydramine; Drug Hypersensitivity; Female; Glucocorticoids; Histamine H1 Antagonists; Histamine H2 Antagonists; Humans; Injections, Intravenous; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Ranitidine; Retrospective Studies | 2002 |
Hypersensitivity reaction (HSR) to docetaxel after a previous HSR to paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Drug Hypersensitivity; Female; Humans; Middle Aged; Paclitaxel; Taxoids | 2002 |
Hypersensitivity reactions from taxol.
Topics: Adult; Aged; Alkaloids; Antineoplastic Agents, Phytogenic; Cimetidine; Colonic Neoplasms; Dexamethasone; Drug Administration Schedule; Drug Hypersensitivity; Female; Humans; Hypersensitivity, Immediate; Leukemia, Myeloid, Acute; Male; Melanoma; Middle Aged; Paclitaxel; Premedication | 1990 |
Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma.
Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Cimetidine; Dexamethasone; Diphenhydramine; Drug Administration Schedule; Drug Evaluation; Drug Hypersensitivity; Humans; Infusions, Intravenous; Kinetics; Melanoma; Neoplasms; Nervous System Diseases; Neutropenia; Paclitaxel | 1987 |
Phase I trial of taxol in patients with advanced cancer.
Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Blood Cell Count; Dose-Response Relationship, Drug; Drug Evaluation; Drug Hypersensitivity; Hematopoiesis; Humans; Nervous System Diseases; Paclitaxel; Pharmaceutical Vehicles | 1987 |
Phase I study of taxol administered as a short i.v. infusion daily for 5 days.
Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Dose-Response Relationship, Drug; Drug Hypersensitivity; Female; Hematopoiesis; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Paclitaxel; Pharmaceutical Vehicles | 1987 |
Taxus baccata allergy in a breast cancer patient.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Immunologic; Drug Hypersensitivity; Female; Humans; Taxoids; Taxus | 2012 |